Effets de l'alendronate et de l'alfacalcidol sur l'os chez les patients myasthéniques traités par glucocorticoïdes.

Rubrique ouverte à tous en lecture seule.
POUR ACCEDER AUX NOMBREUX AUTRES FORUMS IL EST NECESSAIRE DE S'INSCRIRE (fonction M'enregistrer en haut à droite de l'écran).
Répondre
Avatar du membre

Auteur du sujet
Pboulanger
Administrateur
Administrateur
Messages : 5163
Enregistré le : 02 févr. 2010 18:41
Localisation : La Chapelle en Serval F-60520
    Windows 10 Firefox
Genre :
Zodiaque :
Âge : 61
Contact :
France

Effets de l'alendronate et de l'alfacalcidol sur l'os chez les patients myasthéniques traités par glucocorticoïdes.

Message par Pboulanger » 29 déc. 2017 09:55

:hi:

:arrow: Lu sur :https://www.ncbi.nlm.nih.gov/pubmed/29266368

Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum

Image

Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment.
Lv F1, Guan Y2, Ma D1, Xu X1, Song Y1, Li L1, Jiang Y1, Wang O1, Xia W1, Xing X1, Li M1.
Clin Endocrinol (Oxf). 2017 Dec 20. doi: 10.1111/cen.13537.


Abstract
  • OBJECTIVE:

    Glucocorticoids (GCs) are the first-line treatment for myasthenia gravis (MG) and act as long-term immunosuppressants. However, GCs can induce osteoporosis and bone fractures. In this study, we evaluate the effects of oral alendronate and alfacalcidol, or alfacalcidol alone on the bone of Chinese patients with MG who will initiate treatment with GCs.
  • DESIGN AND METHODS:

    A total of 75 patients were included in this 12-month prospective, open-label, single-center study. Patients with bone mineral density (BMD) T-score less than -1.0 at baseline were treated with 70 mg of alendronate per week. Patients with BMD T-score greater than -1.0 at baseline were included in the alfacalcidol alone group. Patients in two groups were treated with 0.25 μg of alfacalcidol every other day and 600 mg of calcium daily.
  • RESULTS:

    After 12 months of treatment, the mean BMD of lumbar spine, femoral neck, and total hip increased by 3.4% (p=0.002), 1.8% (p=0.21), and 2.6% (p=0.02), respectively in alendronate group. In alfacalcidol alone group, the mean BMD of lumbar spine, femoral neck, and total hip decreased by 6.1%, 3.2%, and 3.3%, respectively (all p<0.001 vs baseline).
  • CONCLUSIONS:

    We demonstrated for the first time that treatment with alendronate combined with alfacalcidol significantly increased BMD, decreased bone turnover biomarker levels, and reduced the occurrence of hypercalciuria in a large cohort of Chinese MG patients who initiated treatment with glucocorticoids. However, treatment with alfacalcidol alone failed to prevent bone loss in MG patients receiving glucocorticoid therapy.
Lien Google trad https://translate.google.fr/translate?h ... 2F29266368
Message de : Pboulanger  un membre de l'équipe technique
Nous utilisons un service automatique de traduction fourni par YANDEX.
Soyez vigilant sur le risque de contre-sens inhérent à ce genre d'outils.
Amicalement,
Image

Répondre

Retourner vers « Informations »